New Additions to Antag Therapeutics' Leadership Team
Antag Therapeutics, a compelling player in the biopharmaceutical realm focused on innovative obesity treatments, proudly announces the expansion of its senior leadership team. This strategic move comes on the heels of initiating a crucial Phase 1 trial for its GIP receptor antagonist, designated AT-7687. The company is enthusiastic about three notable appointments that promise to fortify its efforts in drug development.
Introducing the New Leaders
The distinguished Dr. Jens Chr. Norrild is set to take on the role of Vice President, Head of Chemistry, Manufacturing and Controls (CMC). With a rich history spanning over 15 years in drug development, Dr. Norrild has already made waves in the industry. His previous position as Chief CDMO Officer at Bioneer witnessed him steering a successful leadership team. His extensive background includes serving as Vice President of CMC & Quality at Cytoki Pharma and significant roles at Novo Nordisk, where he played a pivotal part in bringing various diabetes and obesity drugs forward. With a Ph.D. in carbohydrate chemistry from the Technical University of Denmark and a Master’s in Organic Chemistry from the University of Copenhagen, Dr. Norrild brings a wealth of knowledge to Antag.
Joining him is Dr. Ayna Baladi Nejad, who assumes the role of Director of Clinical Pharmacology. With a robust experience in clinical pharmacology and obesity treatments, Dr. Nejad previously served as Senior Principal Clinical Pharmacology Scientist at Novo Nordisk. Her impressive track record includes leading global programs on drugs such as monlunabant and CagriSema, targeting weight management and type 2 diabetes. She earned her Ph.D. in Health and Medical Sciences from the University of Copenhagen, adding to her solid background in the field.
Finally, Dr. Imke Tiessen steps into the role of Chief of Staff, bringing over five years of valuable leadership support from the Novo Nordisk Foundation Center for Basic Metabolic Research. Her past experiences include serving as Senior Executive Assistant and Innovation Coordinator, driving innovation efforts at the center. Dr. Tiessen holds a Ph.D. in Molecular Biology from the University of Copenhagen and an MSc in Molecular Biomedicine from the University of Münster, Germany, making her an asset to the team.
Leadership's Vision for Antag Therapeutics
In welcoming these new leaders, Jörg Möller, the Chief Executive Officer of Antag Therapeutics, expressed enthusiasm: “We are thrilled to have Jens, Ayna, and Imke join our team. Their expertise is invaluable as we advance AT-7687 through its clinical phases. Each of them brings unique experiences that will not just move our projects forward but also help shape the future of obesity treatment. Our commitment remains unwavering: to offer patients an effective obesity treatment option that exceeds the traditional GLP-1-based therapies in terms of weight loss and tolerability.”
The Promise of AT-7687
Antag Therapeutics continues to explore innovative approaches to treating obesity through its exciting compound AT-7687. This drug is built upon groundbreaking insights into GIP receptor antagonism realized by celebrated researchers Professors Jens Juul Holst and Mette Rosenkilde. The therapeutic promise of AT-7687 is underscored by strong preclinical data complemented by compelling human genetic validation. Research indicates that a reduction in GIP receptor activity correlates with leaner body composition, thus fueling the excitement around this investigational treatment.
About Antag Therapeutics
Antag Therapeutics is at the forefront of biopharmaceutical innovation, aiming to redefine treatment paradigms in obesity and cardiometabolic diseases through GIP receptor antagonism. The company’s commitment to alleviating significant medical needs drives its mission to develop advanced pharmaceutical solutions, making a real difference in patients' lives.
Frequently Asked Questions
What is the primary focus of Antag Therapeutics?
Antag Therapeutics focuses on developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism.
What roles have been filled in the leadership team?
The newly appointed leadership team includes Dr. Jens Chr. Norrild as VP of CMC, Dr. Ayna Baladi Nejad as Director of Clinical Pharmacology, and Dr. Imke Tiessen as Chief of Staff.
What is AT-7687?
AT-7687 is a GIP receptor antagonist currently undergoing Phase 1 clinical trials, aimed at improving obesity treatment options.
What is the significance of the appointments at Antag?
The new hires bring extensive experience and expertise to advance the development of Antag's innovative obesity treatment solutions.
How does Antag Therapeutics plan to advance its mission?
By leveraging the unique expertise of its leadership team, Antag aims to deliver differentiated and effective treatments that meet patient needs in obesity management.
